With #malaria #vaccines on the market, we're developing next-gen vaccines and monoclonal antibodies to bring us closer to #malariaeradication. Read about the @who.int-commissioned impact value assessment of malaria vaccines and prophylactic #mAbs in the pipeline: shorturl.at/CgG0J
shorturl.at
Value profile for Malaria vaccines and monoclonal antibodies
Malaria remains a leading cause of morbidity and mortality and is responsible for over 0.5 million annual deaths globally. During the first two decade…